上海医药：硫酸艾沙康唑原料药上市申请获批

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient [1] Group 1 - The approved drug, Sulfate Isavuconazole, is a triazole antifungal medication [1] - Isavuconazole is a prodrug that is rapidly converted into its active metabolite, Isavuconazole, by plasma esterases in the body [1]